Clinical trial • Phase I • Oncology
MEN2501 for Platinum-resistant ovarian cancer | Ovarian cancer
Phase I trial of MEN2501 for Platinum-resistant ovarian cancer | Ovarian cancer. 97 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Platinum-resistant ovarian cancer | Ovarian cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 24-11-2025
- First CTIS Authorization Date
- 23-03-2026
Trial design
Phase I trial across 6 sites in Spain.
- Target Sample Size
- 97
Eligibility
Recruits 97 No vulnerable populations selected; only female subjects are eligible; consent or assent handling not specified in the provided record..
- Vulnerable Population
- No vulnerable populations selected; only female subjects are eligible; consent or assent handling not specified in the provided record.
Recruitment
- Planned Sample Size
- 97
- Recruitment Window Months
- 26
Geography
- Total Number Of Sites
- 6
- Total Number Of Participants
- 97
Spain
- Earliest CTIS Part Ii Submission Date
- 25-02-2026
- Latest Decision Or Authorization Date
- 23-03-2026
- Processing Time Days
- 26
- Number Of Sites
- 6
- Number Of Participants
- 23
Sites
- Site Name
- Clinica Universidad De Navarra
- Department Name
- 034-02: Oncología
- Principal Investigator Name
- Antonio Jose Gonzalez Martin
- Principal Investigator Email
- agonzalezma@unav.es
- Contact Person Name
- Antonio Jose Gonzalez Martin
- Contact Person Email
- agonzalezma@unav.es
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- 034-05: Oncologia Médica y Hematologia
- Principal Investigator Name
- José Alejandro Pérez Fidalgo
- Principal Investigator Email
- afidalgo@incliva.es
- Contact Person Name
- José Alejandro Pérez Fidalgo
- Contact Person Email
- afidalgo@incliva.es
- Site Name
- Instituto Oncologico Dr. Rosell S.L.
- Department Name
- 034-03: Oncology
- Principal Investigator Name
- Alejandro Adolfo Martínez Bueno
- Principal Investigator Email
- amartinez@oncorosell.com
- Contact Person Name
- Alejandro Adolfo Martínez Bueno
- Contact Person Email
- amartinez@oncorosell.com
- Site Name
- Hospital Universitario Quironsalud Madrid
- Department Name
- 034-01: Medical Oncology
- Principal Investigator Name
- Valentina Boni
- Principal Investigator Email
- vboni@nextoncology.eu
- Contact Person Name
- Valentina Boni
- Contact Person Email
- vboni@nextoncology.eu
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- 034-04: Oncology
- Principal Investigator Name
- Ramon Yarza Barrio
- Principal Investigator Email
- ramon.yarza@startmadrid.com
- Contact Person Name
- Ramon Yarza Barrio
- Contact Person Email
- ramon.yarza@startmadrid.com
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- 034-06: Medical Oncology
- Principal Investigator Name
- Ainhoa Madariaga
- Principal Investigator Email
- ainhoama@hotmail.com
- Contact Person Name
- Ainhoa Madariaga
- Contact Person Email
- ainhoama@hotmail.com
Sponsor
Primary sponsor
- Full Name
- Stemline Therapeutics Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- MEN2501
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)